Showing 1401-1410 of 1517 results for "".
Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.Natural Products that Exhibit Antifungal Activity
https://practicaldermatology.com/topics/general-topics/natural-products-that-exhibit-antifungal-activity/20360/Can natural products fight the fungus among us?Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20513/Psychodermatology: A Review
https://practicaldermatology.com/topics/practice-management/psychodermatology-a-review/21180/Psoriasis, Biologics, and Cardiovascular Disease: The Heart of the Matter
https://practicaldermatology.com/topics/psoriasis/psoriasis-biologics-and-cardiovascular-disease-the-heart-of-the-matter/23215/A relationship between increased cardiovascular events in patients with psoriasis has implications for management of this chronic disease.JAK Inhibitors in Hidradenitis Suppurativa: A Systematic Review
https://practicaldermatology.com/topics/feature/jak-inhibitors-in-hidradenitis-suppurativa-a-systematic-review/29887/Hidradenitis suppurativa (HS) is a chronic, disfiguring, debilitating, inflammatory disorder that is characterized by inflammatory nodules, abscesses, fistulae/ sinus tracts, and scarring to the axilla, inframammary folds, and groin.Complications of Biologic Therapy for Psoriasis: Part II
https://practicaldermatology.com/topics/psoriasis/complications-of-biologic-therapy-for-psoriasis-part-ii/22039/Therapeutic success requires clinicians to understand emerging and established safety concerns.- Study: Test Improves the Risk Stratification of Patients with Stage I Melanomahttps://practicaldermatology.com/news/study-finds-decisiondx-melanoma-significantly-improves-the-risk-stratification-of-patients-with-stage-i-melanoma-compared-to-american-joint-committee-on-cancer-8th-edition-staging/2462252/Results from a recent study showed the potential of a 31-gene expression profile (31-GEP) test in improving the prognosis for patients diagnosed with stage I cutaneous melanoma. Despite being considered at low risk for metastasis or melanoma-specific death, patients with stage I cutaneous
- Medicis Announces Winners of First Annual I Acanya Succeed Scholarship Programhttps://practicaldermatology.com/news/20131007-medicis_announces_winners_of_first_annual_i_acanya_succeed_scholarship_program/2459442/Medics, a division of Valeant Pharmaceuticals North America LLC, recently announced the winners of its first I Acanya Succeed scholarship program, an education-based initiative that provides scholarships to college students who h
- BioFactura Starts Phase I Study of BFI-751, a Stelara Biosimilarhttps://practicaldermatology.com/news/biofactura-starts-phase-i-study-of-bfi-751-a-stelara-biosimilar/2460811/BioFactura is set to begin a pivotal pharmacokinetics Phase 1 clinical trial for its Ustekinumab biosimilar BFI-751. The first-in-human Phase I study will assess the effects on healthy human volunteers compared to the biologic medicine, Stelara. This is the first time BFI-751 has been a